home · filing · 0001493152-22-002107
8-K filed January 24, 2022, 6:59 PM ET
ticker DXR
CIK 0000027367
leadership
confidence high
sentiment neutral
materiality 0.30
Daxor appoints Caleb DesRosiers to Board of Directors
DAXOR CORP
Caleb DesRosiers, JD, MPA, appointed to Board effective January 18, 2022, until next annual meeting.
Currently senior principal at Valuate Healthcare (part of Omnicom); previously Chief Strategy Officer at PrescribeWellness.
Board determined Mr. DesRosiers meets NYSE independence standards and qualifies under Regulation S-K Item 407(a).
He has no beneficial ownership of Daxor stock or rights to acquire stock as of appointment date.
Will receive standard non-employee director compensation as described in the company's proxy statement.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Appointed
Caleb DesRosiers
Director
Effective 2022-01-18
Filed January 24, 2022, 6:59 PM ET
On January 18, 2022, Caleb DesRosiers, JD, MPA was appointed to the Board of Directors.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Caleb DesRosiers was appointed as Director at DAXOR CORP.
Action appointed
Role Director
Exact text from the filing
On January 18, 2022, Caleb DesRosiers, JD, MPA was appointed to the Board of Directors.
View on SEC.gov
Source: SEC EDGAR
accession 0001493152-22-002107
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.